Search results (171)
« Back to News & OpinionNews and Opinion from the Pandemic Sciences Institute at the University of Oxford
Human movement drove the rapid early spread of the 2026 Bundibugyo virus outbreak, major DRC-led study finds
16 Nov, 2026
BVD cases doubled roughly every 10 days during the early phase of the outbreak — and anonymized mobility data predicted where the virus would strike next with 96% accuracy, a new paper in Science, led by DRC institutions with collaboration across 25 organisations spanning four continents shows.
Oxford-developed vaccine recommended to enter pivotal trial against deadly Bundibugyo virus
5 Nov, 2026
A vaccine candidate developed by scientists at the University of Oxford has been recommended to enter a pivotal Phase 2/3 clinical trial in the Democratic Republic of the Congo (DRC), in a significant step towards tackling Bundibugyo virus, a potentially deadly pathogen for which no vaccine is currently approved.
Q&A: Could a ‘super’ El Niño increase infectious disease risks in the UK?
3 Nov, 2026
Expanding on a recent editorial, PSI’s Dr Jake Dunning, also co-director of the NIHR HPRU-EZI, raises awareness of a potential increase in travel-associated infections during the 2026-27 El Niño event.
Fair and timely vaccine-sharing rules could save more lives globally
20 Oct, 2026
- Epidemiology & data
- Ethics, social science & humanities
- Research news
- Vaccines, treatments, diagnostics & trials
In a recently published policy brief led by UNU-INWEH, PSI authors and colleagues call for an equity-focused global mechanism to improve vaccine financing, production and delivery before the next pandemic.
Oxford-coordinated research embedded in the frontline Ebola response
19 Oct, 2026
Researchers from PSI are working alongside Congolese and international partners to deliver a major clinical trial within the frontline humanitarian response to the Bundibugyo Ebolavirus outbreak in the Democratic Republic of the Congo (DRC).
Uganda launches Phase I clinical study of ChAdOx1 BDBV vaccine
6 Oct, 2026
The study is part of an international effort to develop vaccines against Ebola virus species for which no licensed vaccines are currently available.
New study supports WHO emergency guidance on investigational use of Ervebo vaccine during Bundibugyo outbreak
8 Sep, 2026
PSI researchers and colleagues found evidence of cross-reactive response to Bundibugyo ebolavirus among Ervebo vaccine recipients and survivors of the 2013—2016 West African Ebola epidemic, providing evidence in support of a Phase 3 clinical trial.
100th patient enrolled in PARTNERS clinical trial of treatments for Bundibugyo ebolavirus disease
12 Aug, 2026
This milestone, reached just 12 weeks after the announcement of the outbreak, makes PARTNERS the fastest-ever randomised controlled trial of treatments for Ebola.
Early-career researchers shine at the International Pandemic Sciences Conference in Singapore
29 Jul, 2026
Conference recognises next generation of leaders in pandemic sciences research.
First volunteer vaccinated in the world's first Bundibugyo ebolavirus vaccine trial
24 Jul, 2026
The milestone marks the first time the ChAdOx1 BDBV vaccine has been administered to humans.
Patient enrolment begins in PARTNERS trial to identify the first effective treatments for Bundibugyo virus disease
2 Jul, 2026
An international collaboration between the Institut National de Recherche Biomédicale (INRB) Democratic Republic of the Congo, the Institute of Tropical Medicine (ITM), Antwerp, and the University of Oxford, the trial will evaluate potential therapies for Bundibugyo virus disease.
PSI’s continued involvement in UK-PHRST to reinforce epidemic preparedness globally
26 Jun, 2026
The expanded UK Public Health Rapid Support Team, including institutions from the UK, Africa and Southeast Asia, has now received £18m in funding for the next five years.
Oxford Bundibugyo ebolavirus vaccine candidate receives CEPI backing
1 Jun, 2026
The Coalition for Epidemic Preparedness Innovations (CEPI) has announced today that it will urgently accelerate the development of three investigational vaccines targeting the Bundibugyo ebolavirus that has caused a rapidly spreading epidemic in the Democratic Republic of the Congo (DRC) and neighbouring Uganda, including one being developed by the Oxford Vaccine Group at the University of Oxford.
Media spotlight: PSI experts on Bundibugyo Ebola vaccines and treatments
28 May, 2026
Several UK and global outlets have covered Oxford’s response to the Bundibugyo Ebola virus outbreak currently affecting the DRC and Uganda.
Statement on vaccine efforts relating to the Bundibugyo Ebolavirus outbreak in the DRC
22 May, 2026
In response to the current Bundibugyo Ebolavirus outbreak in the Democratic Republic of the Congo, the Oxford Vaccine Group (OVG) is working urgently with Oxford’s own Clinical BioManufacturing Facility and the Serum Institute of India Pvt. Ltd. (SIIPL), to rapidly produce and scale doses of our ChAdOx-based monovalent Bundibugyo Ebolavirus candidate vaccine, ChAdOx1 BDBV.
UK launches a study of Andes hantavirus using a pre-approved outbreak protocol
21 May, 2026
Study uses ISARIC's globally recognised Clinical Characterisation Protocol
Decentralising disease surveillance and modelling approaches will support equitable infectious disease responses
21 May, 2026
By sharing data analytics instead of raw data, federated approaches enable surveillance and modelling while respecting ethical and legal boundaries.
Major European study warns current measures failing to halt spread of ‘superbugs’
14 May, 2026
New data from 37 countries reveals the escalating threat of carbapenem-resistant K. pneumoniae and identifies ‘warning signals’ for E. coli, prompting calls for global genomic surveillance.
Improving early diagnosis of HIV and Hepatitis B and C with machine learning algorithms
12 May, 2026
The BMC Infectious Diseases study is the first to investigate the integration of machine learning algorithms with primary care data to support testing for blood-borne diseases.
Media Spotlight: PSI experts comment on hantavirus outbreak
11 May, 2026
PSI members have provided expert comment on the recent hantavirus outbreak across a range of media.